Solutions
Our products
A rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the potential generation of resistance associated with topical antibiotics and other antimicrobials.
Steriwave treatment destroys nasal pathogens (including Staphylococcus aureus, Candida auris, SARS-CoV-2, MRSA and other superbugs) significantly reducing a person’s risk of infection or passing these pathogens along to others. Over the past decade, Steriwave has helped Vancouver General Hospital to reduce its surgical site infections (SSIs) by up to 84%.
In addition to our lead product, Steriwave, we also have a number of products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce SARS-CoV-2 titre and transmission.
